G-CSF PEG-G-CSF Market

Granulocyte colony-stimulating factor (G-CSF) is a protein that stimulates white blood cell production in the bone marrow. White blood cells are essential in the fight against infection. G-CSF is used to treat cancers such as leukemia and lymphoma, as well as to boost white blood cell counts in people who have had chemotherapy or radiation therapy.

Pegfilgrastim (Neulasta) is a long-acting version of G-CSF. It is administered as a shot under the skin every four weeks. The increasing prevalence of cancer and the growing number of patients undergoing chemotherapy and radiation therapy are driving the growth of the G-CSF PEG-G-CSF market. The risks of G-CSF PEG-G-CSF use include febrile neutropenia, anemia, thrombocytopenia, and headache.

The process of attaching a polyethylene glycol (PEG) polymer chain to another larger molecule is known as PEGylation (in this case, G-CSF or PEG-G-CSF). PEGylation hides a protein from immune recognition, reduces immunogenicity, and increases the circulating half-life. Increased half-life enables improved efficacy and lower dosing frequency. The global G-CSF PEG-G-CSF market is expected to grow as the incidence of cancer and blood disorders rises, as does the use of biologics in these indications.

Biosimilar maturation is also expected to contribute to market growth, as biosimilars are typically less expensive than reference products and provide greater patient access. Furthermore, several clinical trials are currently underway to evaluate G-CSF PEGylated constructs in various cancers and blood disorders. Successful clinical outcomes from these trials would boost market growth even further.

Some of the major players include Apotex Inc., Cadila Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC., Accord Healthcare, NAPP PHARMACEUTICALS LIMITED., Intas Pharmaceuticals Ltd., and Mundipharma International.